Brief: Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Curis

05/12/2023 13:24

Dec 5 (Reuters) - Curis Inc  CRIS.O :
    * CURIS ENTERS INTO AGREEMENT FOR EMAVUSERTIB /
PEMBROLIZUMAB
COMBINATION STUDY IN MELANOMA
    * CURIS INC - CURIS IS RESPONSIBLE FOR SUPPLY OF EMAVUSERTIB
    * CURIS INC: MERCK IS RESPONSIBLE FOR SUPPLY OF
PEMBROLIZUMAB AND
CLINICAL STUDY COSTS
    * CURIS INC - BOTH COMPANIES RETAIN 100% OF COMMERCIAL
RIGHTS TO
THEIR RESPECTIVE PROGRAMS
    * CURIS INC: STUDY IS EXPECTED TO BEGIN ENROLLMENT IN FIRST
HALF
2024

Source text for Eikon:  ID:nPnsQx4Ca 
Further company coverage:  CRIS.O 

 ((Reuters.Briefs@thomsonreuters.com;))